|
|
|
|
|
|
Sponsors and Collaborators: |
Dana-Farber Cancer Institute Brigham and Women's Hospital Massachusetts General Hospital |
Information provided by: | Dana-Farber Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00165217 |
The purpose of this study is to collect information about the antitumor activity and the safety of capecitabine and thalidomide in patients with colorectal cancer.
Condition | Intervention | Phase |
Colorectal Adenocarcinoma |
Drug: Capecitabine Drug: Thalidomide |
Phase II |
MedlinePlus related topics: | Cancer Colorectal Cancer |
Drug Information available for: | Thalidomide Capecitabine |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma |
Estimated Enrollment: | 37 |
Study Start Date: | November 2001 |
Study Completion Date: | December 2005 |
Primary Completion Date: | December 2005 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Massachusetts | |||||
Dana-Farber Cancer Institute | |||||
Boston, Massachusetts, United States, 02115 | |||||
Massachusetts General Hospital | |||||
Boston, Massachusetts, United States, 02114 |
Dana-Farber Cancer Institute |
Brigham and Women's Hospital |
Massachusetts General Hospital |
Principal Investigator: | Charles S. Fuchs, MD, MPH | Dana-Farber Cancer Institute |
Study ID Numbers: | 01-141 |
First Received: | September 9, 2005 |
Last Updated: | December 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00165217 |
Health Authority: | United States: Institutional Review Board |
|
|
|
|
|